10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Excellent Response with Ado-Trastuzumab Emtansine in a Patient with Relapsed Metastatic Breast Cancer Presenting with Pulmonary Lymphangitic Carcinomatosis

      case-report
      1 , , 2 , 3
      ,
      Cureus
      Cureus
      breast cancer, trastuzumab, t-dm1, her2

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In breast cancer, aggressive tumor biology and the corresponding poor prognosis is associated with amplification or overexpression of the human epidermal growth factor receptor 2 (HER2). Trastuzumab has significantly changed the natural history of HER2-positive breast cancer. However, resistance to trastuzumab remains a substantial clinical problem. Ado-trastuzumab emtansine (T-DM1), an antibody-drug conjugate, has demonstrated impressive results in second- or later-line treatment of HER2-positive breast cancer. We report a case of 43-year-old female with previously trastuzumab-treated HER2-positive breast cancer relapsed with pulmonary lymphangitis carcinomatosis that responded dramatically to T-DM1 therapy. 

          Related collections

          Most cited references2

          • Record: found
          • Abstract: found
          • Article: not found

          Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.

          In the randomised, parallel assignment, open-label, phase 3 TH3RESA study, progression-free survival was significantly longer with trastuzumab emtansine versus treatment of physician's choice in previously treated patients with HER2-positive advanced breast cancer. We report results from the final overall survival analysis of the TH3RESA trial.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Cancer Statistics

            (2017)
              Bookmark

              Author and article information

              Journal
              Cureus
              Cureus
              2168-8184
              Cureus
              Cureus (Palo Alto (CA) )
              2168-8184
              14 July 2017
              July 2017
              : 9
              : 7
              : e1473
              Affiliations
              [1 ] Department of Hematology and Oncology, William Beaumont Hospital, Oakland University William Beaumont School of Medicine
              [2 ] Department of Internal Medicine, William Beaumont Hospital, Oakland University William Beaumont School of Medicine
              [3 ] Department of Hematology and Oncology, William Beaumont Hospital, Oakland University William Beaumont School of Medicine
              Author notes
              Article
              10.7759/cureus.1473
              5598866
              55070aa8-b33f-44aa-857e-09bb10f2ff88
              Copyright © 2017, Yu et al.

              This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

              History
              : 22 May 2017
              : 14 July 2017
              Categories
              Oncology
              Oncology

              breast cancer,trastuzumab,t-dm1,her2
              breast cancer, trastuzumab, t-dm1, her2

              Comments

              Comment on this article